Zacks Research Has Positive View of Omnicell FY2027 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Stock analysts at Zacks Research lifted their FY2027 EPS estimates for Omnicell in a note issued to investors on Thursday, March 5th. Zacks Research analyst Team now forecasts that the company will earn $1.13 per share for the year, up from their prior estimate of $1.11. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2027 earnings at $0.30 EPS and FY2028 earnings at $1.44 EPS.

A number of other analysts also recently issued reports on the stock. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a report on Wednesday, January 7th. Wells Fargo & Company raised their price target on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Piper Sandler restated an “overweight” rating and issued a $49.00 target price (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Wall Street Zen lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Benchmark upped their target price on Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $54.50.

Omnicell Stock Performance

Shares of OMCL opened at $42.25 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.00. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of 1,056.51, a PEG ratio of 1.49 and a beta of 0.79. The business has a 50-day simple moving average of $44.71 and a two-hundred day simple moving average of $38.20.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The business had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

Institutional Investors Weigh In On Omnicell

Several large investors have recently added to or reduced their stakes in OMCL. AQR Capital Management LLC grew its stake in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after buying an additional 5,311 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after purchasing an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after acquiring an additional 4,866 shares during the period. Jane Street Group LLC boosted its position in Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after purchasing an additional 109,382 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Omnicell in the 2nd quarter valued at about $282,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 2.52% of the stock is owned by company insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.